

Biocompatibles' Clinical Trial Programme

Hepatocellular Carcinoma	
Trial Details	Status
Prospective Randomised Study of Transarterial Doxorubicin-Eluting Bead Embolisation vs Conventional TACE in the Treatment of Patients with Hepatocellular Carcinoma on the Liver Transplant Waiting List <i>Charité Universitätsmedizin, Berlin, Germany</i>	Recruiting
Assessment of Chemoembolisation using Doxorubicin-Eluting Beads in Patients Listed for Orthotopic Liver Transplantation with Hepatocellular Carcinoma with Explant Correlation <i>Auckland City Hospital, New Zealand</i>	Recruiting
LC Drug-Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed (HCC) <i>University of Pittsburgh Medical Center, PA, USA</i>	Recruiting
A Pilot Study of Neoadjuvant Therapy for Hepatocellular Carcinoma using Doxorubicin-Eluting Embolic Beads <i>Mount Sinai Hospital, New York, USA</i>	Recruiting
Chemoembolisation of Hepatocellular Carcinoma with Drug-Eluting Beads: Efficacy and Doxorubicin Pharmacokinetics (PRECISION II) <i>Barcelona Clinic Liver Cancer (BCLC), Spain</i>	Published:
Journal of Hepatology 46 (2007) 474-481	
A Phase I/II Trial of Chemoembolization for Hepatocellular Carcinoma using a Novel Intra-arterial Drug-Eluting Bead (PRECISION III) <i>Queen Mary Hospital, Hong Kong</i>	Published:
Journal Clinical Gastroenterology and Hepatology 5 (2007) 1100-1108	
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V) <i>International multicentre RCT, Austria, France, Germany, Greece and Switzerland</i>	Published Online:
Cardiovasc Intervent Radiol 33 (2010) 41-52	
Doxorubicin-eluting Bead-enhanced Radiofrequency Ablation of Hepatocellular Carcinoma: a Pilot Clinical Study <i>Cisanello University Hospital, Pisa, Italy</i>	Published:
Journal of Hepatology 49 (2009) 217-212	
Prospective Randomised Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma <i>University of Athens, Greece</i>	Published:
Cardiovasc Intervent Radiol 33 (2010) 541-551	
Single Centre Phase II Trial of Transarterial Chemoembolization with Drug-Eluting Beads for Patients with Unresectable Hepatocellular Carcinoma <i>Johns Hopkins University Medical School, Baltimore, USA</i>	Published:
The Cancer Journal 15 (2009) 526-532	
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination with Transarterial Chemoembolization (TACE) Performed with DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC) <i>International Multicentre RCT, sponsored by Bayer</i>	Recruiting

Hepatic Metastases	
Trial Details	Status
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastases from Colon Cancer with Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy	Recruiting
Pilot study (n=10) complete	
Chemoembolisation with Irinotecan-Loaded DC Bead* (DEBIRI) in Combination with Cetuximab in the First-line Treatment of Patients with KRAS Wild-type Metastatic Colorectal Cancer (mCRC)	Protocol in development
A Single-arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients with Resectable Liver Metastases from Colorectal Cancer	Recruiting
A Randomised Phase II Trial of Irinotecan Drug-Eluting Beads Administered by Hepatic Chemoembolisation with Cetuximab (IV) vs Systemic Treatment with Irinotecan (IV) plus Cetuximab (IV) in Patients with Refractory Metastatic Colorectal Cancer and KRAS Wild-type Tumours	Recruiting
DC Bead /LC Bead International Registry	Recruiting
Chemoembolisation of Liver Metastases from Breast Carcinoma with Doxorubicin-Loaded DC Bead	Protocol in development
Transcatheter Arterial Chemoembolisation (TACE) with Doxorubicin-Loaded LC Bead in the Treatment of Liver Metastases in Patients with Stage IV Metastatic Melanoma: A Multicenter Pilot, Non-Randomised Feasibility Trial	Recruiting
Transarterial Chemoembolisation of Liver Metastases from Well Differentiated Gastroenteropancreatic Endocrine Tumours with Doxorubicin-Eluting Beads	Published
JVIR 19 (6) 2008	

The products may not be available for sale, may not be registered, approved or cleared for use as claimed, in all countries where Biocompatibles is represented.

The views and opinions expressed in this document are those of the author and may not reflect those of Biocompatibles. The author acted as a consultant for Biocompatibles, for which payment was made.

Lipectol is a registered trademark of Guerbet SA. Embosphere is a registered trademark of Biosphere Medical, Inc. DC Bead is a registered trademark and LC Bead, Bead Block, DEBDOX and DEBIRI are trademarks of Biocompatibles UK Ltd. DC Bead is not currently available for sale or distribution in the USA. © 2010 Biocompatibles UK Ltd. EC10-109 Rev 1.